ClinicalTrials HQ

Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Active, not recruiting · NCT05753384 · Registry updated 2026-04-27
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune SystemChronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasmActive, not recruitingPhase 32026-04-27NCT05753384

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Poitiers University Hospital76

20 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Centre Léon BérardLyonFrance71
CH AnnecyAnnecyFrance3
CH BayonneBayonneFrance5
CH Brive la GaillardeBrive-la-GaillardeFrance1
Ch ChamberyChambéryFrance2
Ch La RochelleLa RochelleFrance6
CH Mont de MarsanMont-de-MarsanFrance4
Ch PerigueuxPérigueuxFrance4
CH VersaillesVersaillesFrance4
CHI CreteilCréteilFrance2
CHU AngersAngersFrance87
CHU BrestBrestFrance37
CHU LilleLilleFrance63
CHU LimogesLimogesFrance42
CHU NancyNancyFrance24
CHU NantesNantesFrance86
CHU PoitiersPoitiersFrance70
CHU ToursToursFrance36
Hopital Prive Du ConfluentNantesFrance3
Oncopole ToulouseToulouseFrance3